SNPMiner Trials (Home Page)
Report for Clinical Trial NCT00672035
Developed by Shray Alag, 2020-2021.
SNP Clinical Trial Gene
The main purpose of this study is to evaluate the body's immune response to the LT patch at
The secondary purpose of this study is to evaluate the safety of the LT patches at different
doses and the safety of the skin preparation system. Another secondary purpose is to compare
the safety and the body's immune response to LT patches placed on the upper arm versus the
NCT00672035 Traveler's Diarrhea
Name: Biological: heat-labile enterotoxin of E. coli (LT)
Description: LT patch applied on either the deltoid or the lower back.
Group Labels: 10 1 10 2 3 4 5 6 7 8 9
Primary Outcomes Measure: To evaluate the immunogenicity of LT application at different doses Time: 6 months
Secondary Outcomes Measure: To evaluate the safety of LT application at different doses Time: 6 months
Measure: To evaluate the safety of the skin preparation system Time: 6 months
Measure: To compare patch performance (safety and immunogenicity) on different anatomical parts of the body Time: 6 months
There is one SNP
- Ever received investigational enterotoxigenic E. coli, LT, or LT(R192G) or NasalFlu,
Berna Biotech, Ltd.
- Ever received cholera toxin or vaccine (e.g. --- R192G ---